

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 9, 2007

Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)

Florida	000-27836	65-0643773
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2 Snunit Street
Science Park
POB 455
Carmiel, Israel 21000

(Address of principal executive offices) (Zip Code)

Orthodontix, Inc.

(Former Name or Former Address, if Changed Since Last Report)

Registrant's telephone number, including area code: +972-4-988-9488

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On March 9, 2007, Protalix BioTherapeutics, Inc. (the "Company") issued a press
release announcing that its common stock had been approved for listing on the
American Stock Exchange. The Company's common stock is expected to commence
trading on the American Stock Exchange under the ticker symbol PLX on Monday,
March 12, 2007. The approval is contingent upon the Company being in compliance
with all applicable listing standards on the date it begins trading on the
American Stock Exchange, and may be rescinded if the Company is not in
compliance with such standards.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated March 9, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

(Registrant)

Date: March 12, 2007

By: /s/ David Aviezer

Name: David Aviezer, Ph.D.
Title: President and
Chief Executive Officer

Protalix BioTherapeutics, Inc. to Commence Trading on
the American Stock Exchange

Shares to Trade under the Symbol PLX

Carmiel, Israel - March 9, 2007 - Protalix BioTherapeutics, Inc. (OTC Bulletin Board: PXBT) today announced that its common stock has been approved for listing on the American Stock Exchange. Protalix's common stock is expected to commence trading on the American Stock Exchange under the ticker symbol PLX on Monday, March 12, 2007. Protalix has selected Weiskopf Silver & Co. as its specialist.

David Aviezer, Ph.D., President and CEO of Protalix said, "This listing represents a significant milestone for Protalix following the completion of our merger with Orthodontix, Inc. We believe that listing our shares on the American Stock Exchange will provide us with an effective outlet through which to communicate continued progress in our clinical development and the anticipated commercialization of our products under development."

Dr. Aviezer added, "I am confident that our listing on a national stock exchange will benefit our shareholders through improved visibility and liquidity for our shares. We are pleased to have qualified for this listing, and look forward to a long and mutually beneficial relationship with the American Stock Exchange."

This approval is contingent upon Protalix being in compliance with all applicable listing standards on the date it begins trading on the Exchange, and may be rescinded if Protalix is not in compliance with such standards.

About Protalix BioTherapeutics, Inc.

Protalix's proprietary technology is based on its plant cell culture and bioreactor system which provides an effective and scaleable cell system for industrial production of recombinant biopharmaceuticals. Protalix has recently announced that it has completed Phase I clinical studies for its enzyme therapy for Gaucher Disease, under an FDA Investigational New Drug study. Protalix intends to pursue advanced clinical studies for its enzyme therapy for Gaucher Disease and advance additional recombinant biopharmaceutical drug development programs.

Safe Harbor Statement:

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies and products under development, the identification of lead compounds, the successful preclinical development of our products, the completion of clinical trials, the review process of the FDA, foreign regulatory bodies and other governmental regulation, and other factors described in our filings

with the Securities and Exchange Commission. The statements are valid only as of the date hereof and Protalix disclaims any obligation to update this information.

For additional information, contact:

David Aviezer, CEO
972-4-988-9488